7 citations
,
August 2021 in “Journal of the European Academy of Dermatology and Venereology” This study suggests that early initiation of treatment in fibrosing alopecia in a pattern distribution may lead to a more favorable outcome, as evident in some patients experiencing arrested disease progression and hair regrowth.
4 citations
,
July 2023 in “Frontiers in Microbiology” HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.
In this study, a 75% ethanol extract of Fructus Psoraleae was found to significantly inhibit 5-α reductase and promote hair growth in mice, indicating its potential as a treatment for androgenetic alopecia through modulation of the Nrf2-Keap1 pathway.
This study found a significant discordance between clinical symptoms and dermatoscopic signs with histopathological inflammation in patients with LPP and AFF, affecting diagnostic and therapeutic approaches.
October 2024 in “Journal of the Endocrine Society” This case study describes a 45-year-old man who developed post-finasteride syndrome with various symptoms after stopping Finasteride, highlighting the condition's rarity and poorly understood pathophysiology.
May 2025 in “Journal of Cosmetic Dermatology” This research emphasizes the importance of integrating pre-treatment psychological assessments for individuals considering finasteride, highlighting that these assessments could help identify those prone to nocebo responses, potentially reducing adverse symptom development more related to cognitive vulnerabilities than to the drug itself.
September 2021 in “Clinical research in dermatology” This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.
May 2021 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” This article evaluates clinical and scientific literature on post-finasteride syndrome, concluding that finasteride and dutasteride may cause persistent sexual, neurological, and physical adverse side effects in a subset of men.
117 citations
,
March 2013 in “Journal of the European Academy of Dermatology and Venereology” This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.
July 2021 in “British Journal of Dermatology” In this study, the researchers reported that early diagnosis and treatment of fibrosing alopecia in a pattern distribution may arrest or potentially reverse disease progression, though some patients experienced continued hair loss.
June 2025 in “International Journal of Computational Intelligence Systems” This study introduces a novel computational model using fuzzy logic and multi-criteria decision-making techniques to create a triage system for androgenetic alopecia management, stratifying patients into seven severity levels and aiding in resource allocation and treatment planning.
9 citations
,
January 2015 in “Current problems in dermatology” This review discusses partial longitudinal-follicular unit transplantation (PL-FUT) for hair loss and notes its potential to multiply hair follicles while preserving donor areas, but reports no new clinical results.
September 2021 in “CRC Press eBooks” This review discusses the clinical and trichoscopic features of lichen planopilaris and notes its potential underdiagnosis prior to hair transplant, but it reports no new findings.
September 2022 in “The American journal of dermatopathology/American journal of dermatopathology” In this pilot study, researchers found no sunscreen particles in the hair follicle units of patients with frontal fibrosing alopecia, suggesting no direct link between sunscreen use and the condition.
January 1988 in “Toxicological Sciences” In this study, a single oral dose of 2,3,4,7,8-pentachlorodibenzofuran in male Fischer rats led to dose-dependent toxicity, resulting in weight loss, hepatotoxicity, and mortality.
March 2023 in “Journal of Cosmetic Dermatology” This case report illustrates that fibrosing alopecia in a pattern distribution may be misdiagnosed as androgenetic alopecia due to similar hair loss patterns, but distinctive trichoscopic and histopathologic features help differentiate it.
8 citations
,
August 2017 in “Skin appendage disorders” Red dots on the upper chest may be an early sign of certain types of hair loss.
September 2023 in “Journal of the American Academy of Dermatology” This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.
2 citations
,
July 2021 in “The Journal of Sexual Medicine” This study found significant differences in gene expression, particularly in androgen receptor activity, between men with post-finasteride syndrome and healthy controls, suggesting a potential biological basis for the syndrome.
This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.
13 citations
,
April 2022 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” This comprehensive literature review highlighted that lichen planopilaris and frontal fibrosing alopecia, both primary scarring alopecias, are diagnosed via scalp biopsy, with no standardized treatments available, necessitating individualized therapeutic approaches based on patient characteristics.
March 2026 in “Frontiers in Immunology” In this study, a 49-year-old female with metastatic adrenocortical carcinoma experienced an abscopal effect following pulse electric field ablation, suggesting potential as an adjunct to systemic immunotherapy for liver tumors.
30 citations
,
January 2020 in “Fertility and Sterility” This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This presentation argues that post-exposure syndromes like PSSD and Long COVID form a coherent group of conditions driven by complex interactions in high-dimensional state spaces rather than singular molecular pathways.
December 2024 in “Brazilian Journal of Health Review” This article reviews the general, pathophysiological, diagnostic, and therapeutic aspects of alopecia frontal fibrosante, highlighting its irreversible nature and the importance of early diagnosis, but it reports no new clinical results.
1 citations
,
December 2024 in “Archives of Iranian Medicine” This study found that tofacitinib significantly improved disease activity in most patients with LPP, though further research is needed to refine protocols, understand response predictors, and address gender-specific adverse effects.
37 citations
,
April 2019 in “Journal of The American Academy of Dermatology” This review assessed the effectiveness of various treatments for frontal fibrosing alopecia and found that intralesional steroids and 5α-reductase inhibitors showed the most positive outcomes in slowing or halting hair loss, though the lack of placebo-controlled studies and consistent outcome measures limits definitive conclusions.
1 citations
,
May 2021 in “Clinical Nuclear Medicine” In this study, 18F-FDG PET/CT revealed increased FDG uptake in the scalp of a woman after platelet-rich plasma therapy, indicating potential inflammatory changes.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.
34 citations
,
August 2011 in “Journal of Natural Medicines” This study found that Puerariae Flos extract inhibited testosterone 5α-reductase and promoted hair growth in mouse models, suggesting its potential use for treating androgenic alopecia.